Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Human bone marrow-derived, pooled, allogeneic mesenchymal stromal cells manufactured from multiple donors at different times show comparable biological functions in vitro, and in vivo to repair limb ischemia

Fig. 2

In vitro immunosuppression of alloreactive MLRs by Stempeucel®-1 and Stempeucel®-1A. a Suppression of MLR by mitomycin C-arrested Stempeucel®-1 (n = 15) and Stempeucel®-1A (n = 4) at three MLR: MSC ratios of 1:1, 1:2.5, and 1:10; MLR proliferation and suppression was measured by BrdU incorporation measurement as described in the “Methods” section. b Percentage of cells positive for HLA-DR in Stempeucel®-1 (n = 3) and Stempeucel®-1A (n = 3) cells at the basal level and after priming with TNFα and IFN-γ showed significant difference (***P = 0.0007). c Immunosuppression activity was retained in both Stempeucel®-1 and Stempeucel®-1A upon inflammatory priming at all three ratios of IFN-γ and TNFα primed, high HLA-DR expressing Stempeucel®-1 and Stempeucel®-1A cells did not reduce their immunosuppression capacity and a trend towards higher immunosuppression by primed cells was seen compared to unprimed controls. Graphs represent mean ± SD values; ns – not significant

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512